Table 2.

Comparison of NT-proXNP, NT-proANP, and NT-proBNP concentrations in healthy persons and in patients with VHD or CAD.

NT-proXNPNT-proANPNT-proBNP
Healthy women,1 pmol/L (n = 50)148 (102–206)2249 (196–292)88 (55–117)
Healthy men,1 pmol/L (n = 50)114 (82–148)228 (169–315)80 (69–96)
VHD patients,1 pmol/L (n = 111)1113 (553–1963)1181 (702–1648)421 (200–867)
Best VHD cutoff,3 pmol/L303416169
 Mean (95% CI) sensitivity, %88 (81–94)89 (82–94)79 (71–86)
 Mean (95% CI) specificity, %100 (96–100)94 (87–98)100 (96–100)
CAD patients,1 pmol/L (n = 367)445 (262–782)4563 (364–884)4177 (90–355)4
Best CAD cutoff,3 pmol/L248408127
 Mean (95% CI) sensitivity, %78 (73–82)69 (64–74)64 (59–69)
 Mean (95% CI) specificity, %95 (89–98)93 (86–97)91 (84–96)
Patients separated by left ventricular function1
 LVEF5 >50%, pmol/L (n = 370)465 (265–860)582 (369–966)179 (93–364)
 LVEF = 41–50%, pmol/L (n = 64)666 (35–1324)f758 (438–1335)g283 (137–563)f
 LVEF = 31–40%, pmol/L (n = 30)978 (614–1822)g1154 (624–1763)g405 (258–805)f
 LVEF ≤30%, pmol/L (n = 13)2418 (1230–3834)f1585 (1264–2198)g1105 (548–1635)f